Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/12456
|
| Title: | Activity of ceftolozane-tazobactam against Gram-negative pathogens isolated from lower respiratory tract infections in the Asia-Pacific region: SMART 2015-2016 |
| Authors: | Kuo, SC;Liu, CE;Lu, PL;Chen, YS;Lu, MC;Ko, WC;Hsueh, PR;Chuang, YC;Wang, FD;the SMART Asia-Pacific Group |
| Contributors: | National Institute of Infectious Diseases and Vaccinology |
| Abstract: | This study aimed to investigate the susceptibility of respiratory Gram-negative bacteria to ceftolozane/tazobactam and other antibiotics in the Asia-Pacific region during 2015-2016. MICs were determined using the CLSI standard broth microdilution method and interpreted accordingly. Pseudomonas aeruginosa (1574 isolates), Klebsiella pneumoniae (1226), Acinetobacter baumannii (627) and Escherichia coli (476) accounted for 73.1% of 5342 Gram-negative respiratory pathogens. The susceptibility to ceftolozane/tazobactam of individual Enterobacteriaceae was >80%, except Enterobacter cloacae (76.6%). Ceftolozane/tazobactam inhibited 81.9% of K. pneumoniae and 91.9% of E. coli, with respective MIC50/MIC90 values of 0.5/>32 and 0.25/2 mg/L. For carbapenem-susceptible, ESBL-producing K. pneumoniae and E. coli, susceptibility was 65.5% and 93.3% and respective MIC50/MIC90 values were 2/>32 and 0.5/2 mg/L. BlaCTX-M-1 group was most prevalent in selected ESBL-producing K. pneumoniae (40 of 54) and E. coli (15 of 22) isolates, with ceftolozane/tazobactam susceptibility rates of 50% and 80%, respectively. BlaSHV-ESBL was the second most prevalent, and ceftolozane/tazobactam inhibited 20% of 20 K. pneumoniae isolates with blaSHV-ESBL. The only effective antibiotics for carbapenem-non-susceptible K. pneumoniae (111 isolates) and E. coli (24 isolates) were amikacin and colistin. Ceftolozane/tazobactam was effective against almost all P. aeruginosa and carbapenem-non-susceptible strains (333 isolates), with susceptibility of 92.3% and 72.8%, respectively; the respective MIC50/MIC90 values were 1/4 and 2/>32 mg/L. The high susceptibility of ceftolozane/tazobactam remained in different age groups, patient locations, recovery times and countries, except Vietnam. In conclusion, ceftolozane/tazobactam was effective against most respiratory Gram-negative pathogens in the Asia-Pacific region. However, the emergence of carbapenem resistance mandates ongoing surveillance. |
| Date: | 2020-03 |
| Relation: | International Journal of Antimicrobial Agents. 2020 Mar;55(3):Article number 105883. |
| Link to: | http://dx.doi.org/10.1016/j.ijantimicag.2020.105883 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0924-8579&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000518855500001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85078496364 |
| Appears in Collections: | [郭書辰] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB31923574.pdf | | 796Kb | Adobe PDF | 314 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
